Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Boehringer Ingelheim advances cancer antibody-drug conjugate portfolio with asset from AimedBio

Collaboration and license agreement will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with a new asset expected to enter first-in-human studies next year.New, potentially best-in-class ADC is targeting a tumor selective marker present in a broad spectrum of cancers with…